All Outputs (3)

PEGylation of recombinant human deoxyribonuclease I decreases its transport across lung epithelial cells and uptake by macrophages (2020)
Journal Article
Mahri, S., Hardy, E., Wilms, T., De Keersmaecker, H., Braeckmans, K., De Smedt, S., …Vanbever, R. (2021). PEGylation of recombinant human deoxyribonuclease I decreases its transport across lung epithelial cells and uptake by macrophages. International Journal of Pharmaceutics, 593, Article 120107. https://doi.org/10.1016/j.ijpharm.2020.120107

Conjugation to high molecular weight (MW ≥ 20 kDa) polyethylene glycol (PEG) was previously shown to largely prolong the lung residence time of recombinant human deoxyribonuclease I (rhDNase) and improve its therapeutic efficacy following pulmonary d... Read More about PEGylation of recombinant human deoxyribonuclease I decreases its transport across lung epithelial cells and uptake by macrophages.

Biodistribution and elimination pathways of PEGylated recombinant human deoxyribonuclease I after pulmonary delivery in mice (2020)
Journal Article
Mahri, S., Rondon, A., Wilms, T., Bosquillon, C., & Vanbever, R. (2021). Biodistribution and elimination pathways of PEGylated recombinant human deoxyribonuclease I after pulmonary delivery in mice. Journal of Controlled Release, 329, 1054-1065. https://doi.org/10.1016/j.jconrel.2020.10.034

Conjugation of recombinant human deoxyribonuclease I (rhDNase) to polyethylene glycol (PEG) of 20 to 40 kDa was previously shown to prolong the residence time of rhDNase in the lungs of mice after pulmonary delivery while preserving its full enzymati... Read More about Biodistribution and elimination pathways of PEGylated recombinant human deoxyribonuclease I after pulmonary delivery in mice.

Development of an in vitro system to study the interactions of aerosolized drugs with pulmonary mucus (2020)
Journal Article
Alqahtani, S., Roberts, C. J., Stolnik, S., & Bosquillon, C. (2020). Development of an in vitro system to study the interactions of aerosolized drugs with pulmonary mucus. Pharmaceutics, 12(2), Article 145. https://doi.org/10.3390/pharmaceutics12020145

© 2020 by the authors. Licensee MDPI, Basel, Switzerland. Mucus is the first biological component inhaled drugs encounter on their journey towards their pharmacological target in the upper airways. Yet, how mucus may influence drug disposition and ef... Read More about Development of an in vitro system to study the interactions of aerosolized drugs with pulmonary mucus.